Cidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel DFCs comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment. Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation.
Looking for a particular Cidara Therapeutics employee's phone or email?
The Cidara Therapeutics annual revenue was $54.3 million in 2026.
Jeff Stein is the President and CEO of Cidara Therapeutics.
51 people are employed at Cidara Therapeutics.
Cidara Therapeutics is based in San Diego, California.
The NAICS codes for Cidara Therapeutics are [541, 5417, 541711, 54, 54171, 32541, 3254, 325414, 32, 325].
The SIC codes for Cidara Therapeutics are [283, 28].